Shedding Light on Type 2 Diabetes: Weight Management & Future Breakthroughs | Weight Management as a Treatment for T2D: Novel Pharmacological Approaches

Estimated Time
0.5 hr

Release Date
Apr 30, 2024

Expiration Date
Oct 31, 2025

Activity Description
Healthcare providers (HCPs) encounter significant challenges when treating patients with type 2 diabetes (T2D). HCPs should be cognizant of when to change or intensify treatment and be aware of options that are non-optimal. As such, HCPs need to be equipped with current professional guidelines, the latest clinical evidence on new and emerging therapies for T2D, and strategies for engaging patients in shared decision-making to effectively prioritize weight management and promote comprehensive T2D care.

Explore the 3-part on-demand series, Shedding Light on Type 2 Diabetes: Weight Management & Future Breakthroughs. This collaborative effort, in conjunction with local AAFP Chapter meetings, provides expert guidance and clinical best practices to understand the impact of weight on T2D outcomes, weight management as a treatment for T2D, and effective strategies for shared decision-making in T2D care. Key topics in Part 2: Weight Management as a Treatment for T2D: Novel Pharmacological Approaches include: 

  • Mechanistic drivers of T2D pathophysiology and the role of emerging treatment options: Review. How incretin-based drugs’ mechanism of action is effective in treating patients with T2D, with a focus on disease pathophysiology
  • Evidence-based approaches in the treatment of T2D in accordance with ADA/EASD guidelines: Assess. Both current standards of care in T2D and the latest clinical evidence of new and emerging incretin-based treatments

Don't miss the opportunity to join this series and learn in person, gaining valuable insights into effectively addressing T2D for improved patient health. Be sure to take part 2 and part 3 to maximize your education and impact!

Speakers

Accreditation and Disclosure Information

Educational Objectives
After completing this activity, the participant should be better able to:

  • Consistently employ the latest clinical data and mechanisms of action for new and emerging treatment options for T2D, including GLP-1RAs and GIP/GLP-1RAs when developing comprehensive treatment plans


Program Agenda 

  • Mechanistic drivers of T2D pathophysiology and the role of emerging treatment options
  • Evidence-based approaches in the treatment of T2D in accordance with ADA/EASD guidelines


Target Audience
This activity is directed towards U.S. primary care physicians, NPs, and PAs including those who are community-based, practice in large ACOs; in rural communities; and who serve patients in underserved areas.


Accreditation, Support and Credit
 

 

Joint Accreditation with Commendation LogoIn support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


AAFP CME Credit
Joint Accreditation with Commendation LogoThe AAFP has reviewed Shedding Light on Type 2 Diabetes: Weight Management & Future Breakthroughs | Weight Management as a Treatment for T2D: Novel Pharmacological Approaches and deemed it acceptable for up to 0.50 Enduring Materials, Self-Study AAFP Prescribed credits. Term of Approval is from 04/30/2024 to 04/30/2025. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).


Physician Associate
Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until October 31, 2025. PAs should only claim credit commensurate with the extent of their participation


Interprofessional Continuing Education (IPCE) Statement
 This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

 



Commercial Support
Statement This activity is supported by an educational grant from Eli Lilly and Company.


Disclosure & Conflict of Interest Policy
Medical Learning Institute, Inc. is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.


Faculty Disclosures
Chair/Planner/Presenter
Chuck Vega, MD

Clinical Professor, UC Irvine Department of Family Medicine
Assistant Dean for Culture and Community Education
UC Irvine School of Medicine
Santa Ana, CA, USA

Chuck Vega, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: GlaxoSmithKline, Boehringer Ingelheim

Planner/Presenter
Martin J. Abrahamson, MD, FACP

Associate Professor of Medicine
Harvard Medical School
Boston, MA, USA

Martin J. Abrahamson, MD, FACP, has a financial interest/relationship or affiliation in the form of:
The following relationships have ended within the last 24 months:
Advisory Board/Consultant: WebMD Health Services (ended December, 2023)

All of the relevant financial relationships of individuals for this activity have been mitigated.


Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies unless listed below.


Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.


Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and the activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute, Inc.

For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

If you have questions regarding your certificate, please contact via email at mvu@mlieducation.org.

For Physicians, if requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.


About This Activity
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.

Copyright © 2024 Medical Learning Institute, Inc. All Rights Reserved.